Targeting the PI3K/Akt pathway using OSU03012 has proven advantageous in both neuroblastomas [141] and medulloblastomas [142], showing a reduced MYC transcriptional output as well as affecting the stability of MYC proteins. Here, MYC is linked to medulloblastoma.